Yann Vano

5.7k total citations · 2 hit papers
83 papers, 2.4k citations indexed

About

Yann Vano is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yann Vano has authored 83 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 51 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in Yann Vano's work include Renal cell carcinoma treatment (53 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Renal and related cancers (22 papers). Yann Vano is often cited by papers focused on Renal cell carcinoma treatment (53 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Renal and related cancers (22 papers). Yann Vano collaborates with scholars based in France, Belgium and United States. Yann Vano's co-authors include Wolf H. Fridman, Stéphane Oudard, Catherine Sautès‐Fridman, Nicolás A. Giraldo, Étienne Becht, Florent Petitprez, Xavier Cathelineau, Pierre Validire, Alexandre Ingels and Rafael Sanchez‐Salas and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Yann Vano

77 papers receiving 2.4k citations

Hit Papers

The clinical role of the TME in solid cancer 2015 2026 2018 2022 2018 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The clinical role of the TME in solid cancer
    2018 487 citations Nicolás A. Giraldo, Yann Vano et al. profile →
  2. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
    2015 356 citations Nicolás A. Giraldo, Étienne Becht et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yann Vano France 23 1.4k 1.2k 770 603 547 83 2.4k
Jong‐Mu Sun South Korea 25 1.3k 0.9× 1.1k 0.9× 528 0.7× 226 0.4× 431 0.8× 82 2.1k
S. Cedrés Spain 20 1.3k 0.9× 1.2k 1.0× 363 0.5× 305 0.5× 272 0.5× 80 2.2k
Jinming Yu China 19 1.2k 0.9× 671 0.6× 579 0.8× 501 0.8× 456 0.8× 66 2.3k
David Garfield United States 22 1.1k 0.7× 1.2k 1.0× 769 1.0× 235 0.4× 622 1.1× 52 2.4k
C. Lewanski United Kingdom 16 2.4k 1.7× 1.7k 1.4× 354 0.5× 587 1.0× 389 0.7× 41 3.0k
Leila Khoja United Kingdom 20 1.7k 1.2× 612 0.5× 416 0.5× 403 0.7× 388 0.7× 50 2.1k
Atsunari Kawashima Japan 25 744 0.5× 724 0.6× 734 1.0× 456 0.8× 471 0.9× 116 1.9k
Florian Gebauer Germany 27 1.4k 1.0× 728 0.6× 638 0.8× 303 0.5× 562 1.0× 113 2.3k
Audrey Mansuet‐Lupo France 22 981 0.7× 722 0.6× 462 0.6× 326 0.5× 321 0.6× 64 1.8k
André P. Fay United States 22 1.3k 0.9× 1.4k 1.2× 674 0.9× 256 0.4× 619 1.1× 117 2.5k

Countries citing papers authored by Yann Vano

Since Specialization
Citations

This map shows the geographic impact of Yann Vano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yann Vano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yann Vano more than expected).

Fields of papers citing papers by Yann Vano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yann Vano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yann Vano. The network helps show where Yann Vano may publish in the future.

Co-authorship network of co-authors of Yann Vano

This figure shows the co-authorship network connecting the top 25 collaborators of Yann Vano. A scholar is included among the top collaborators of Yann Vano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yann Vano. Yann Vano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albigès, Laurence, G. Pignot, Gwénaëlle Gravis, et al.. (2024). Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157). Urologic Oncology Seminars and Original Investigations. 43(5). 332.e19–332.e26.
2.
Alhalabi, Omar, Sylvie Négrier, Yann Vano, et al.. (2023). Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. The Oncologist. 28(5). 433–439. 13 indexed citations
3.
Allory, Yves, Édouard Auclin, Claire Gervais, et al.. (2023). Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies. Bulletin du Cancer. 110(4). 450–462.
4.
5.
Simonaggio, Audrey, et al.. (2022). MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights. International Journal of Molecular Sciences. 23(14). 7649–7649. 19 indexed citations
6.
Vano, Yann, et al.. (2022). Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies. Cancers. 14(24). 6167–6167. 22 indexed citations
7.
Procureur, Adrien, Audrey Simonaggio, Jean‐Emmanuel Bibault, Stéphane Oudard, & Yann Vano. (2021). Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments. Cancers. 13(4). 678–678. 45 indexed citations
8.
9.
10.
Vano, Yann, et al.. (2021). Nouvelles AMMs : association nivolumab et cabozantinib en première ligne du carcinome rénal à cellules claires avancé. Bulletin du Cancer. 108(11). 991–993. 1 indexed citations
11.
Denize, Thomas, Mathilde Sibony, Hélène Blons, et al.. (2020). MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. Modern Pathology. 34(3). 647–659. 18 indexed citations
12.
Auclin, Édouard, Adrien Procureur, Audrey Simonaggio, et al.. (2020). Cabazitaxel Schedules in Metastatic Castration-Resistant Prostate Cancer: A Review. Future Oncology. 17(1). 91–102. 6 indexed citations
13.
Epaillard, Nicolas, Audrey Simonaggio, Réza Elaidi, et al.. (2020). BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bulletin du Cancer. 107(5). eS22–eS27. 35 indexed citations
14.
Auclin, Édouard, Philippe Barthélémy, Petri Bono, et al.. (2019). Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer. 108. 33–40. 95 indexed citations
15.
Vano, Yann, Audrey Simonaggio, Constance Thibault, & Stéphane Oudard. (2018). Immunothérapie des cancers du rein. Bulletin du Cancer. 105. S24–S34.
16.
Giraldo, Nicolás A., Étienne Becht, Yann Vano, et al.. (2017). Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 23(15). 4416–4428. 263 indexed citations
17.
Petitprez, Florent, Yann Vano, Étienne Becht, et al.. (2017). Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunology Immunotherapy. 67(6). 981–988. 88 indexed citations
18.
Fournier, Laure, Alexandre Bellucci, Yann Vano, et al.. (2017). Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges. PubMed. 1(2). 107–114. 5 indexed citations
19.
Elaidi, Réza, Yann Vano, Nicolas Aide, et al.. (2016). Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases. Annals of Oncology. 27. vi295–vi295. 36 indexed citations
20.
Giraldo, Nicolás A., Étienne Becht, Franck Pagès, et al.. (2015). Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research. 21(13). 3031–3040. 356 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jong‐Mu Sun Breakdown of academic impact, for papers by S. Cedrés Breakdown of academic impact, for papers by Jinming Yu Breakdown of academic impact, for papers by David Garfield Breakdown of academic impact, for papers by C. Lewanski Breakdown of academic impact, for papers by Leila Khoja Breakdown of academic impact, for papers by Atsunari Kawashima Breakdown of academic impact, for papers by Florian Gebauer Breakdown of academic impact, for papers by Audrey Mansuet‐Lupo Breakdown of academic impact, for papers by André P. Fay
Rankless by CCL
2026